About Apollo

We are a portfolio biotech; developing a broad range of drug programs to generate value for our stakeholders; patients, inventors and investors.

We are building a diversified clinical-stage portfolio of assets focused on high-value markets. We have over 20 programs in our core areas of biological focus cell signaling, cell stress response and immunology.

We are a team of experienced drug hunters backed by specialist long-term investors.

We build upon our collaborations with five of the world’s leading research universities, selecting and progressing high-potential discovery programs.

Our Process

Differentiated scientific access

Unique partnerships with five leading global research organisations with over 10,000 biomedical researchers.

Excellence in decision-making

Team of experienced drug-hunters with translational biology and clinical expertise, expert R&D advisory committee, board of proven company-builders.

High capital efficiency

Lean operating model with centralized expert leadership and highly outsourced execution, low fixed costs.

Strong, diversified pipeline

Over 20 programs across our areas of translational biology leadership; cell signalling, cell stress responses and cell metabolism, and immunology.

History

Apollo Timeline

2016

Formation

Apollo Therapeutics initially founded as partnership between three leading research organisations, Cambridge University, Imperial College London and University College London, and three global pharmaceutical companies, AstraZeneca, GSK and J&J with initial $50m committed.

First programs in-licensed

2020

2016-2020

Expanded development activity building portfolio of 15+ pre-clinical programs.

Successful out-licensing of three programs

2021

Series B financing

Series B financing led by Patient Square Capital raises $145m supporting expanded management team

2022

New research partnerships

Kings College London and the Institute of Cancer Research join as research partners of Apollo

2022

In-licensing of camoteskimab

Apollo announces licensing agreement with AstraZeneca for camoteskimab, a clinical-stage monoclonal antibody for Il-18

2023

Series C financing

Series C financing led by Patient Square Capital joined by a number of new investors, including M&G plc, raises $226.5m to advance Apollo portfolio

Connect with Us

Interested in learning more about Apollo? Contact us today. We look forward to hearing from you.